通化东宝出海迎新进展，利拉鲁肽获巴西GMP证书

Core Viewpoint - Tonghua Dongbao's liraglutide injection has received GMP certification from Brazil's ANVISA, marking a significant step in the product's compliance process in the Latin American market and strengthening its internationalization strategy for GLP-1 products [1][2] Group 1: Product and Market Development - Liraglutide, a GLP-1 analog, activates GLP-1 receptors to promote insulin secretion, improve blood sugar levels, and provide cardiovascular protection and weight loss benefits, gaining global recognition for its efficacy and safety [1] - Brazil, with a population of approximately 210 million and a growing diabetes patient base, presents a strong market demand for GLP-1 products, which are effective in glycemic control and weight management [2] Group 2: International Strategy and Achievements - Since 2025, Tonghua Dongbao has accelerated its internationalization strategy, achieving significant progress in overseas registrations and expanding its product matrix in international markets [2] - The recent GMP certification in Brazil, following similar achievements in Colombia and Peru, indicates a systematic layout in the Latin American market and lays a foundation for entering other PIC/S member countries [2] Group 3: Competitive Landscape - The domestic market for GLP-1 drugs in China is highly competitive, and obtaining the GMP certification in Brazil opens a new sales channel for Tonghua Dongbao, helping to extend the product lifecycle and realize incremental value in overseas markets [2]